Meiji Seika Pharma Co.

Yokohama-shi, Japan

Meiji Seika Pharma Co.

Yokohama-shi, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Meiji Seika Pharma Co. | Date: 2017-07-12

The present invention provides a crystal form of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5methylphenol which is stable and high purity for preservation, industrial manufacturing, and circulation, and its preparation process, and specifically, the present invention provides, by using a boron compound, stable and high purity crystals of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol and the preparation process thereof.


Patent
Meiji Seika Pharma Co. and The Kitasato Institute | Date: 2017-04-17

An objective of the present invention is to provide novel cyclic depsipeptide derivatives and harmful organism control agents including the same as each other. Specifically, the present invention provides compounds represented by formula (1) or stereoisomers thereof, harmful organism control agents containing them, and a process for producing them.


Patent
Meiji Seika Pharma Co. | Date: 2017-01-18

A method for producing a compound represented by formula (I) comprises the steps of:acylating an amino group at position 2 of a compound represented by formula (A) by use of trifluoroacetic acid as an acylating agent to thereby produce a compound represented by formula (B); andfurther alkylating a nitrogen atom at position 1 of the compound represented by formula (B), as follows


Patent
Meiji Seika Pharma Co. | Date: 2015-03-04

A method for producing a compound represented by formula (I) comprises the steps of:


Patent
Kyoto Prefectural University and Meiji Seika Pharma Co. | Date: 2017-06-14

A novel plant growth-promoting agent and a plant growth-promoting method using the same are provided. The plant growth-promoting agent contains a lactic acid bacterium having a plant growth-promoting action. Also, in the plant growth-promoting method, a seed, a plant body and/or a soil is treated with a lactic acid bacterium having a plant growth-promoting action. Lactobacillus plantarum strain FERM BP-21501 is suitable as the lactic acid bacterium having a plant growth-promoting action.


Patent
Mitsui Chemicals Inc. and Meiji Seika Pharma Co. | Date: 2017-01-03

What is aimed at is provision of an inexpensive and efficient saccharification method for lignocellulose using a thermostable xylanase and provision of a mutant xylanase that has a substitute amino acid residue, and that exhibits stable activity even under severe conditions in which enzymes easily inactivate, and that provides an initial rate of reaction not significantly reduced as compared to a wild-type xylanase corresponding to the mutant xylanase. Provided is a method of producing a saccharified product of lignocellulose, including contacting a lignocellulosic raw material with a thermostable xylanase, and a mutant xylanase that provides an initial rate of reaction that is at least 70% of that provided by a wild-type xylanase corresponding thereto, that has a xylanase activity after heat treatment at 50 C. for 24 hours that is at least 50% of its xylanase activity before the heat treatment, and that has a substitute amino acid residue.


Patent
Meiji Seika Pharma Co. and Dong A Socio Holdings Co. | Date: 2017-04-19

The present invention provides a stable aqueous adalimumab formulation by incorporating a histidine buffer solution and a phosphate buffer solution in combination. The incorporation of the histidine buffer solution and the phosphate buffer solution makes it possible to improve the stability of adalimumab.


Patent
Meiji Seika Pharma Co. | Date: 2016-05-18

Provided is a compound represented by formula (1a) or a pharmacologically acceptable salt thereof However, R^(1) to R^(6) in the formula each independently represent an alkyl group or the like.


Patent
Meiji Seika Pharma Co. | Date: 2016-03-25

A compound of formula (Ie): wherein Ar, R_(1), R_(4c )and Y are as defined herein and a method of controlling pests using the compound.


The present invention provides crystalline forms of a diazabicyclooctane derivative represented by the following Formula (VII), particularly Formula (VII-1), and processes for producing the same.

Loading Meiji Seika Pharma Co. collaborators
Loading Meiji Seika Pharma Co. collaborators